ARCHIVES

Over $20 Million Carved Out From Statistical, Operations Centers

This article is from The Cancer Letter archive.

Vol. 40 No. 20 | May 16, 2014

Download PDF Visit The Full Archive

Related Articles

Study Uncovers New Mechanism In Class of Chemotherapy Drugs

November 30, 2012

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

January 21, 2005

In Brief: Advisory Committee On Women’s Health Chartered; CALGB Lists New Address

May 12, 1995

NCAB Okays Effort To Relax $5 Million Limit On Center Core Grants In Cancer Act Renewal

November 19, 1976

FDA News: Zydelig approved in three B-cell blood cancers

August 1, 2014

Comprehensive Centers Should Emphasize New Treatment, Group Says

July 27, 1979